ProCE Banner Activity

Considerations in Selecting Therapy for Previously Treated CLL

Slideset Download
Download this slideset from a live symposium at ASH 2022 for expert perspectives on best practices in treating patients with relapsed/refractory CLL.

Released: December 09, 2022

Expiration: December 08, 2023

Share

Faculty

Jennifer A. Woyach

Jennifer A. Woyach, MD

D. Warren Brown Professor of Leukemia Research
Division of Hematology
The Ohio State University
Columbus, Ohio

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

BeiGene

Lilly

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Faculty Disclosure

Primary Author

Jennifer A. Woyach, MD

D. Warren Brown Professor of Leukemia Research
Division of Hematology
The Ohio State University
Columbus, Ohio

Jennifer Woyach, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo, NewWave, Pharmacyclics; researcher: Schrödinger.